Inspire Corporate Bond Impact ETF IBD 深 沪
已收盘 11-14 16:00:00 美东时间
24.08
-0.080
-0.33%
华盛通- 最 高24.26
- 今 开24.26
- 成交量 5.75万股
- 最 低 24.08
- 昨 收 24.16
- 总市值 3.88亿
- 52周最高 24.5952
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 22.1565
- 委 比 50.00%
- 总股本 1610.16万
- 历史最高 24.811
- 量 比 0.97
- 振 幅 0.75%
- 历史最低 16.5325
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sandoz’s Hyrimoz® Study: Real-World Insights into IBD Treatment Retention
Sandoz Group Ltd (($SDZXF)) announced an update on their ongoing clinical study...
10-28 00:50
Spyre Therapeutics Releases New Data From Its Phase 1 Study Of SPY072, An anti-TL1a Antibody For Rheumatic Diseases Showing SPY072 Was Well Tolerated, Maintained Strong Tl1a Suppression, And Supports Quarterly Or Twice-Yearly Dosing
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and
10-24 20:04
8项FDA批准，471个器械获NMPA批准注册文件——医疗器械获批周报（2025.10.10-10.16）
2025年10月10日至10月16日，动脉智库重点整理了医疗器械产品国内外获批资讯及数据，涉及8个器械获FDA批准，2个器械获欧盟及其它批准，另有471个器械获...
10-18 10:05
Spyre Therapeutics Reveals Proposed Public Offering of its Common Stock And Pre-Funded Warrants; No Size Disclosed
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization,
10-14 04:03
First Patient Dosed In Spyre Therapeutics Phase 2 Trial Of SPY072 For Rheumatic Diseases
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
09-15 20:02
Iberdrol增持巴西子公司Neoenergia，比例提升至84%
西班牙私营跨国电气公司伊维尔德罗拉集团（Iberdrola，场外交易代码：IBDRF）通过22亿美元交易将其巴西子公司Neoenergia的持股比例提升至...
09-11 22:38
罗氏(RHHBY.US)4亿美元加码IBD领域 开发临床前口服小分子
9月2日，OMass Therapeutics宣布，已与罗氏集团(RHHBY.US)成员基因泰克(Genentech)达成一项独家合作与许可协议。
09-02 21:15
苹果的AI焦虑：错失浪潮，还是蓄势待发？
随着人工智能席卷全球科技产业，苹果却被质疑在这场关键战役中“缺席”。从Siri推迟至2026年发布，到AI功能的滞后进展，再到股价年内下跌7%，华尔街对苹果的AI战略充满焦虑。
09-01 21:05
长春高新：公司长效生长激素经长期安全验证，国内唯一
8月31日，长春高新（000661.SZ）在电话会议中表示，目前，子公司金赛药业已拥有重组人促卵泡激素粉剂及水剂产品，预计今年一周注射一次的长效FSH水剂可以获...
09-01 14:27
Shattuck Labs IND For SL-325 Now In Effect; Preclinical Data Shows High-Affinity DR3 Binding And Favorable Safety Profile
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –– The Company is on track
08-21 22:19
